outcomes research

Research in Review

Aggressive Care Associated With Poorer Outcomes for Patients With NSCLC at End-of-Life

05/26/2017

JCP Editors

Aggressive care within the last month of life for patients with non-small cell lung cancer (NSCLC) is associated with lower family evaluations of end-of-life care, according to new research. ----- Related...

...

05/26/2017

Journal of Clinical Pathways

Research in Review

ASCT Deemed Safe and Effective for Older Patients With B-Cell Malignancies

05/25/2017

JCP Editors

Older patients with B-cell malignancies benefit from progression-free survival (PFS) and overall survival (OS) improvements after autologous stem cell transplantation (ASCT), according to research that will be...

Older...

05/25/2017

Journal of Clinical Pathways

Research in Review

Triple Combination Active in High-Risk B-Cell Malignancies

05/24/2017

JCP Editors

A combination of 3 pathway inhibitors is well tolerated with activity observed in heavily pre-treated and high-risk B-cell malignancies, according to research that will be presented at the ASCO Annual Meeting (June...

A...

05/24/2017

Journal of Clinical Pathways

Research in Review

Targeted Therapy May Improve Outcomes for Patients With Multiple Myeloma

05/22/2017

JCP Editors

Targeted therapy against a particular protein has the potential to improve outcomes and fracture-free survival for patients with multiple myeloma, according to research that will be presented at the 2017 ASCO...

...

05/22/2017

Journal of Clinical Pathways

Research in Review

Immune Checkpoint Inhibitors May Increase Response to CAR-T Therapy in ALL

05/19/2017

JCP Editors

Pembrolizumab improves response to chimeric antigen receptor (CAR) T-cell treatments in pediatric patients with B-cell relapsed acute lymphoblastic leukemia (ALL), according to research that will be presented at...

...

05/19/2017

Journal of Clinical Pathways

Research in Review

Trastuzumab Emtansine Improves OS in Patients With HER2+ Breast Cancer

05/19/2017

JCP Editors

Patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer benefit from an estimated 7 additional months of survival if treated with trastuzumab emtansine rather than the physician’s choice...

...

05/19/2017

Journal of Clinical Pathways

Research in Review

Targeted Therapy Improves Disease-Free Survival in Intermediate-Risk NSCLC

05/18/2017

JCP Editors

Adjuvant treatment with the targeted therapy gefitinib (Iressa, AstraZeneca) significantly improved disease-free survival (DFS) over standard of care after surgery for patients with non–small cell lung cancer...

...

05/18/2017

Journal of Clinical Pathways

Research in Review

Prostate Cancer Subtypes Respond Differently to Androgen Deprivation Therapy

05/17/2017

JCP Editors

Luminal and basal subtyping of prostate cancer may provide a clinical tool for predicting which patients will benefit from androgen deprivation therapy (ADT) after prostatectomy, according to a report published in...

...

05/17/2017

Journal of Clinical Pathways

Research in Review

PD-L1 Expression Associated With Radiation Resistance in Head and Neck Cancer

05/16/2017

JCP Editors

PD-L1 expression may be a biomarker of local failure in human papillomavirus (HPV)-negative head and neck squamous cell carcinoma following radiotherapy, according to research published in Clinical Cancer Research...

PD-L1...

05/16/2017

Journal of Clinical Pathways

Guideline-Recommended Therapy Underused in Rare Form of Bladder Cancer

05/16/2017

JCP Editors

Recommended primary treatment for non-muscle invasive micropapillary urothelial carcinoma (MPBC) is often foregone in community cancer centers and academic centers, according to a study presented at the American...

...

05/16/2017

Journal of Clinical Pathways